Hematological Toxicity During Concomitant Treatment With Ruxolitinib and Avelumab for Merkel Cell Carcinoma

Background Merkel Cell Carcinoma (MCC) is a rare neuroendocrine skin cancer. It frequently emerges in presence of immunosuppression state as myeloprofiliferative syndromes (MS). MS are treated with Ruxolitinib, a selective JAK1 and JAK2 inhibitor. Avelumab, an Anti PDL-1 inhibitor is MCC standard treatment. At to date is unknown if avelumab and ruxolitinib have a sinergistic or antagonistic effect when used together. Methods We have identified...